HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.3494
+0.0098 (2.89%)
At close: May 13, 2026, 4:00 PM EDT
0.3607
+0.0113 (3.23%)
After-hours: May 13, 2026, 7:24 PM EDT
HCW Biologics Revenue
In the year 2025, HCW Biologics had annual revenue of $54.23K, down -97.89%. HCW Biologics had revenue of $27.01K in the quarter ending December 31, 2025, a decrease of -93.16%.
Revenue (ttm)
$54.23K
Revenue Growth
-97.89%
P/S Ratio
43.39
Revenue / Employee
$1,506
Employees
36
Market Cap
2.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.23K | -2.51M | -97.89% |
| Dec 31, 2024 | 2.57M | -275.00K | -9.68% |
| Dec 31, 2023 | 2.84M | -3.88M | -57.72% |
| Dec 31, 2022 | 6.72M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 5.07M |
| Scinai Immunotherapeutics | 1.31M |
| Biodexa Pharmaceuticals | 104.90K |
| AIM ImmunoTech | 88.00K |
| Virax Biolabs Group | 2.99K |
HCWB News
- 13 days ago - HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum - GlobeNewsWire
- 16 days ago - HCW Biologics to file IND for HCW11-018b in first half of 2027 - TheFly
- 16 days ago - HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors - GlobeNewsWire
- 6 weeks ago - HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results - GlobeNewsWire
- 2 months ago - HCW Biologics closes exclusive worldwide license for HCW11-006 - TheFly
- 2 months ago - HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic - GlobeNewsWire
- 2 months ago - HCW Biologics announces positive research results for CAR-T cell therapy - TheFly
- 2 months ago - HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - GlobeNewsWire